PMID: 6403102Mar 12, 1983Paper

Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes

British Medical Journal
J M LordK G Taylor

Abstract

To investigate the effect of metformin on insulin receptor binding and diabetic control, eight obese type II diabetic patients were studied before treatment, after one and four weeks of taking metformin (500 mg thrice daily), and four weeks after withdrawal of the drug. After one and four weeks of treatment the number of erythrocyte insulin receptors had increased by 116% and 184% respectively. This was due almost entirely to an increase in the number of low affinity binding sites. The number of receptors was still raised four weeks after metformin had been withdrawn. Diabetic control as assessed by urinary glucose, glycosylated haemoglobin (HbA1), and glucose tolerance values was significantly improved during metformin treatment, while plasma insulin concentrations were not altered. These results indicate that metformin produces a rapid and protracted increase in low affinity insulin receptors in type II diabetes, associated with greater insulin sensitivity and improved diabetic control.

References

May 1, 1978·Diabetes Care·H E Lebovitz, M N Feinglos
Jul 1, 1978·Diabetes·K K GambhirC J Bradley
Aug 1, 1978·British Journal of Clinical Pharmacology·M S LennardH F Woods
Apr 1, 1971·Clinica Chimica Acta; International Journal of Clinical Chemistry·J F Stevens
Sep 3, 1981·The New England Journal of Medicine·A HolleH W Rüdiger
Jan 1, 1982·The Journal of Clinical Endocrinology and Metabolism·R VigneriI D Goldfine
Oct 1, 1981·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Jul 1, 1963·The Biochemical Journal·C N HALES, P J RANDLE

❮ Previous
Next ❯

Citations

Sep 1, 1995·Diabetes/metabolism Reviews·S Del PratoA Tiengo
Sep 1, 1995·Diabetes/metabolism Reviews·G Perriello
Jan 1, 1985·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·B FrorathH W Rüdiger
Jun 1, 1988·Diabetologia·F PurrelloI D Goldfine
May 3, 2002·Clinical and Experimental Pharmacology & Physiology·Masami SuzukiHitoshi Ikeda
Aug 15, 1997·Medizinische Klinik·E Haupt, U Panten
Aug 1, 1987·Metabolism: Clinical and Experimental·F PurrelloR Vigneri
Sep 1, 1984·Diabetic Medicine : a Journal of the British Diabetic Association·R Taylor
May 1, 1988·Diabetic Medicine : a Journal of the British Diabetic Association·C J Bailey
Apr 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·O PedersenN Sørensen
Nov 1, 1995·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·R J Mahler
Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·Y MorelG M Reaven
Nov 1, 1985·The Journal of Pharmacy and Pharmacology·J M LordC J Bailey
Mar 8, 2003·International Journal of Immunopathology and Pharmacology·M T GuagnanoS Sensi
Feb 1, 1996·The Annals of Pharmacotherapy·W R Melchior, L A Jaber
May 16, 2020·Cytotechnology·José Manuel Villalva-PérezEugenia Flores-Alfaro
Apr 27, 2021·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Samantha Celeste Garcia-HernandezM Elba Gonzalez-Mejia
Nov 9, 2000·Biochimica Et Biophysica Acta·G J MickK L McCormick
Apr 1, 1991·Biochemical Medicine and Metabolic Biology·K K Gambhir, V R Agarwal
May 1, 1988·Baillière's Clinical Endocrinology and Metabolism·C J Bailey, M Nattrass
May 1, 1986·Pharmacological Research Communications·R I Hoich, F M Ng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.